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Recently, various innovative therapies involving the ex vivo manipulation and
subsequent reintroduction of exosome-based therapeutics into humans have
been developed and validated, although no exosome-based therapeutics have
yet to be brought into the clinic. Exosomes are nanosized vesicles secreted by
many cells that utilize them for cell-to-cell communications to facilitate transport
of proteins and genetic material. Comprised of cellular membranes with multiple
adhesive proteins on their surface, exosomes offer distinct advantages that
exceptionally position them as highly effective drug carriers. Additionally, exo-
somes can exert unique biological activity reflective of their origin that may be
used for therapy of various diseases. In fact, exosomes have benefits of both syn-
thetic nanocarriers and cell-mediated drug delivery systems, and avoid their lim-
itations. This concise review highlights the recent developments in exosome-
based drug delivery systems and the main regulatory considerations for using
this type of therapeutic in clinic. © 2016 Wiley Periodicals, Inc.
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INTRODUCTION
An increasing amount of nanomaterials are beingdesigned to aid in the transport of diagnostic
and therapeutic agents through biologic barriers. A
common approach for building a drug delivery sys-
tem is to incorporate the drug within the nanocarrier
that results in increased solubility, metabolic stability,
and improved circulation time. Several formulations
are being studied in clinical trials, or have already
been approved by the FDA for use in humans.1,2
However, conventional nanoparticles normally are
cleared rapidly from the circulation by the mononu-
clear phagocyte system (MPS).3 Extending the circu-
lation time of these carriers can be accomplished by
decorating these carriers with water-soluble polymers
such as polyethylene glycol (PEG). Although PEGyla-
tion decreases clearance by the MPS, it also reduces
interaction of the nanoformulation with target and
barrier cells, thus decreasing the drug biodistribution
in disease tissues.4–6 In addition, development of an
immune response to the PEG corona significantly
increases the clearance of PEGylated drug
nanocarriers.7–9 In extreme cases, severe allergic reac-
tions to PEG due to immediate exposure to reactive
antibodies in the blood were reported.10 With this
foundation, exosomes have recently emerged as a
promising drug delivery system for various small-
and high-molecular-weight therapeutic agents with
low immunogenicity, low toxicity, and high thera-
peutic efficacy.11 It was suggested that collected from
patients’ tissues or blood, allogenic exosomes should
have immune-privileged status with low clearance by
MPS. Furthermore, the cell source of these extracellu-
lar vesicles (EVs) may determine their biodistribu-
tion, indicating that they may possess an innate
homing ability. In addition, exosomes can be targeted
to specific disease tissues via modifications of their
parental cell, or incorporating of a tissue-specific vec-
tor moiety vector into exosomes. Consequently, an
increasing number of researchers investigate and uti-
lize exosomes for the delivery of low-molecular-
weight therapeutics, nucleic acids, proteins, and even
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viruses. The overall scheme of different approaches
to using exosome-based therapeutic formulations is
depicted in Figure 1.
BIOGENESIS OF EXOSOMES
The unique properties of exosomes can be attributed
to their biogenesis; the classical view of exosome bio-
genesis holds that they are accumulated initially in
multivesicular sacs, i.e., multivesicular bodies
(MVBs) followed by fusion with the plasma mem-
brane and their release.11 Exosomes’ close relative,
microvesicles, are believed to bud directly from the
plasma membrane. They are greater in size
(100–500 nm) than exosomes (40–100 nm) and have
slightly different protein and lipid content.12 Conse-
quently, exosomes and microvesicles are currently
believed to have endosomal and plasma membrane
origin, respectively. Larger vesicles (500–1000 nm)
are considered to be apoptotic bodies. Many investi-
gations, especially in the field of drug delivery, utilize
both exosomes and microvesicles, defining them as
extracellular vesicles, because a complete separation
and purification of each type of vesicles is extremely
laborious and difficult, if not impossible.13
Many cell types actively secrete exosomes, in
particular, cells of the immune system such as den-
dritic cells (DCs),14 macrophages,15 B cells,16 and T
cells,17 as well as mesenchymal stem cells (MSCs),18
endothelial cells,19 and epithelial cells.20 Exosomes
and other types of microvesicles are also secreted
by a variety of cancer cells.21 Exosomes can be iso-
lated from conditioned cell culture media or
bodily fluids by differential centrifugation,14 filtration
paired with centrifugation,14 immunoaffinity,14 size
exclusion chromatography,22 or polymer-based
precipitation,23,24 as well as microfluidic technolo-
gies25,26 utilizing principles from the aforementioned
methods. Each method has its advantages and
disadvantages, requires different methods of prepro-
cessing of samples, and produces exosome prepara-
tions of varying purity and quality.24,27,28 The user
may choose a method for exosome isolation based
on the intended downstream use. Interestingly,
recently a novel approach designed to isolate exo-
somes from freshly removed and frozen mouse and
human brain tissues secreted into brain extracellular
space was developed.29 These exosomes were iso-
lated from brain tissue treated with papain by subse-
quent centrifugation.
EXOSOME CHARACTERIZATION
Exosomes can be characterized by the size and pro-
tein and lipid content. Different techniques were
developed for the characterization of exosomes.
Among them are flow cytometry, Western blotting,
nanoparticle tracking analysis, dynamic light scatter-
ing (DLS), mass spectrometry (MS), and several
microscopy techniques.30 The International Society
for Extracellular Vesicles (ISEV) published a position
paper in 2014, in which the characterization of exo-
somes is recommended by the presence of exosome-
associated surface markers as well as the absence of
proteins not associated with exosomes.31 Exosomal
surface markers include TSG101, Alix, flotillin 1, tet-
raspanins (CD9, CD63, CD81), integrins, and cell
adhesion molecules.31 Regarding lipid content, exo-
somes are highly enriched in cholesterol, sphingomy-
elin, and hexosylceramides at the expense of
phosphatidylcholine and phosphatidylethanola-
mine.32 The fatty acids in exosomes are mostly satu-
rated or monounsaturated. Together with the high
concentration of cholesterol, this may account for
lateral segregation of these lipids into exosomes dur-
ing their formation at MVBs.
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FIGURE 1 | Overview of approach to using exosome-based therapeutic formulations.
PROTECTIVE AND REGENERATIVE
EFFECTS OF EXOSOMES
Exosomes represent important vehicles of intercellu-
lar communication in between cells, and play a vital
role in regulating a broad range of physiological and
pathological cellular processes.33 Some of these func-
tions may be utilized for therapeutic purposes.
One of the major candidates for this role is exo-
somes derived from MSCs.34–42 These cells may orig-
inate from bone marrow, adipose tissue, cord blood,
and other origins. Thus, MSCs-derived exosomes
were reported to produce significant cardioprotective
paracrine effects against myocardial ischemia/reper-
fusion injury in pig and mouse models.35,36 These
exosomes were also beneficial in pulmonary hyper-
tension (HP). HP is a kind of malignant pulmonary
vascular disease characterized by an increase in pul-
monary artery pressure, which may lead to heart fail-
ure and even death. Interestingly, MSCs-derived
exosomes directly suppressed early pulmonary
inflammation and vascular remodeling37 through the
suppression of hyperproliferative pathways, including
signal transducer and activator of transcription 3 -
(STAT3)-mediated signaling. Furthermore, it was
reported that stem cells-derived EVs have the ability
to induce angiogenic programs in quiescent endothe-
lial cells.43 Furthermore, MSCs-derived exosomes
were also shown to have neuroprotective effects in
stroke. It was demonstrated that stroke induces
changes in the microRNA (miRNA) profile of these
exosomes,44,45 especially in miRNAs that actively
participate in the recovery process after stroke.46
MSCs-derived exosomes transferred their therapeutic
factors to recipient cells, altered gene expression, and
thereby promoted neurite growth in rat primary neu-
rons.39 Next, a hepatic regeneration was shown by
use of MSC-derived exosomes in drug-induced liver
injury models.47,48 The higher survival rate was asso-
ciated with upregulation of the priming-phase genes
during liver regeneration, which subsequently led to
higher expression of proliferation proteins (PCNA
and cyclin D1) in the exosome-treated group. Thera-
peutic effects of exosomes derived from human adi-
pose tissue-derived MSCs were also reported for the
treatment of Alzheimer’s disease (AD).38 It was
demonstrated that these exosomes carry enzymati-
cally active neprilysin (NEP), the most important
enzyme that degrades β-amyloid (Aβ) peptide plugs
in the brain. MSCs-derived exosomes decreased both
intracellular and extracellular Aβ levels in a neuro-
blastoma cell line N2A in vitro.
Along with stem cells-derived exosomes, protec-
tive and regenerative effects were reported for
exosomes released by endothelial cells.49 Atheroscle-
rosis, the underlying cause of myocardial infarction
(MI) and stroke, occurs predominantly in predis-
posed spots in the large arteries. Exosomes derived
from endothelial cells were suggested to be a promis-
ing strategy to combat atherosclerosis.49 Systemic
administration of exosomes released from human
umbilical vein endothelial cells (HUVECs) reduced
atherosclerotic lesions in mice fed a high-fat diet.
Exosomes secreted by shear-stress-stimulated
HUVECs were enriched in multiple miRNAs. The
delivery of these miRNAs to smooth muscle cells
(SMCs) resulted in controlled target gene expression
and reduction of atherosclerotic lesion formation in
the mouse aorta.49 Next, exosomes secreted from
cardiosphere-derived cells (CDCs) were also shown
to produce a range of diverse cardioprotective effects,
including anti-inflammatory, antioxidative, antiapop-
totic, antifibrotic, and cardiomyogenic effects.42,50,51
CDCs-released exosomes stimulated angiogenesis,
promoted cardiomyocyte proliferation, and decreased
programmed cell death in vitro. The regenerative
capacity of these exosomes was demonstrated in a
model of chronic MI in rats.52 These diverse effects
were attributed to the ability of exosomes to enhance
neovascularization, cardiomyocyte survival, and to
reduce fibrosis after occurrence of cardiac infarction
via paracrine mechanisms.53
Finally, MVBs have also been identified in
plants, and leaderless secreted proteins can be
released in vesicles, as described recently.54,55 Ju
et al. showed protective effects of exosome-like nano-
particles isolated from crushed grapes.56 In particu-
lar, the oral administration of exosome-like
nanoparticles from grapes to mice led to the signifi-
cant proliferation of the intestinal epithelium. These
exosomes are being tested for their effects on oral
mucositis and related pain after radiotherapeutic and
chemotherapeutic treatment of head and neck can-
cers in an ongoing clinical trial (NCT01668849).
IMMUNE-MODULATING
PROPERTIES OF EXOSOMES
Immunotherapy against various cancer tumors with
autologous exosomes is the area of the most devel-
oped exosome-based therapeutics.57 Thus, two Phase
I clinical trials using exosomes for the treatment of
non-small-cell lung (NSCL) and melanoma cancers
have been successfully completed.58,59 Usually, exo-
somes released by activated antigen-presenting cells,
such as DCs, macrophages, T lymphocytes, or B
cells, are utilized. The presence of MHC class I and
II, as well as T-cell co-stimulatory molecules on the
surface of these exosomes is an important mechanism
of antigen presentation.60 In addition, immune
response cells that were exposed to cancer cells were
shown to package cellular components from these
cancer cells into exosomes and trigger an antitumor
response by presenting tumor antigens to immune
cells.61–67
In particular, DCs-secreted exosomes incubated
with human breast adenocarcinoma cells (SK-BR-3)
were demonstrated to induce tumor-sensitized T cells
to secrete high levels of Interferon-γ (IFN-γ).62
Recently, Di Bonito et al.68 reported that HEK293T
cells, which were transfected with an antigen, HPV-
E7, produced exosomes loaded with the antigen.
These HPV-E7-loaded exosomes produced a similar
cytotoxic CD8+ T-cell response in C57BL/6 mice as
compared to virus-like particles containing the same
antigen when systematically administered in drug-
equivalent amounts. Next, Qazi et al.63 observed a
significant anticancer activity of exosomes secreted
by DCs that were exposed to chicken egg ovalbumin
(OVA). These exosomes elicited specific transgenic T-
cell proliferation in vitro. Furthermore, T-cell-
released exosomes were shown to destroy tumor
stroma and prevent tumor invasion and metastases.64
In addition to the improved immune responses, T-
cell-derived EVs were demonstrated to modulate
endothelial cell responses to vascular endothelial
growth factor (VEGF) and alter tube formation and
gene expression in target endothelial cells.
Importantly, the induction of immune responses
may be mediated not only by the bioactive lipids and
proteins present in exosomes but also by exosome-
and EV-associated RNAs.65 Contained inside exo-
somes, small noncoding RNAs (miRNAs) play a key
role in mediating biological functions owing to their
prominent role in gene regulation. Thus, Aucher
et al.66 reported that human macrophages can trans-
fer miRNAs to hepatocarcinoma cells (HCCs) and
functionally inhibit proliferation of these cancerous
cells. The transport of these miRNA was associated
with EVs.
Aside of antitumor effects, DCs-derived exo-
somes were also shown to improve immune
responses to difteria and Leishmania infections.69,70
Furthermore, exosomes that were found in human
breast milk can boost the immune response and alter
the T-cell balance toward a regulatory
phenotype.71,72
Finally, exosomes can be used for immunosup-
pressive purposes. Thus, immature DCs express a
low ratio of co-stimulatory molecules to co-
regulatory molecules on their surface, and are
therefore immunosuppressive. A treatment with exo-
somes derived from these in vitro-generated immuno-
suppressive DCs reversed early-onset collagen-
induced arthritis even more effectively than the treat-
ment with parental cells.73 Immunosuppressive exo-
somes have also been used in transplantation to
inhibit the alloantigen-related immune responses such
as allograft rejection. Thus, the donor-specific allo-
graft immunosuppression was induced by the co-
treatment with donor DCs-derived exosomes and a
drug that blocks the maturation of recipient DCs.74
DCs-derived exosomes injected before transplanta-
tion significantly prolong heart allograft survival in
congenic and fully MHC-mismatched Lewis rats. In
addition, cardiac endothelial cell-derived exosomes
were shown to induce specific regulatory B cells with
immune suppressor functions.19 Overall, exosomes
are potent immune regulators and may be utilized for
the design of vaccine adjuvants and therapeutic inter-
vention strategies to modulate immune responses.
THERAPEUTIC EFFECTS OF DRUG-
LOADED EXOSOMES
As exosomal carriers can provide advantages of both
cell-based drug delivery and nanotechnology, interest
in using exosomes for drug delivery has exploded in
recent years.75–77 Similar to viruses, these remarkable
carriers are capable of traveling from one cell to
another, easily passing their contents across the cell
membrane owing to their unique characteristics, and
delivering their cargo in a biologically active form.
Noteworthy, exosomes possess an inherent ability to
cross biological barriers, including the most difficult
to penetrate, the blood–brain barrier (BBB).
Exosomes have been exploited as drug delivery
vehicles for small-molecule therapeutic agents in sev-
eral investigations.78–85 In one of the first reports,
exosomes loaded with an anti-inflammatory com-
pound, curcumin, were shown to protect mice from
lipopolysaccharides-induced brain inflammation.78,79
The incorporation of curcumin in exosomes
improved its solubility, increased circulation time,
preserved drug therapeutic activity, and enhanced
drug transport across the BBB. In another study, exo-
somes or exosome-like vesicles loaded with different
chemotherapeutics, doxorubicin (Dox) or paclitaxel
(PTX), were shown to traffic to tumor tissues and
reduce tumor growth in mice without adverse effects
observed with the equipotent free drug.80–82 Notably,
the therapeutic effects of Dox-loaded exosome-
mimetic nanovesicles were greater than the commer-
cially available Dox-loaded liposomes, Doxil; the
liposomal formulation was inefficient in reducing
tumor growth in this model.80 Pascucci
et al. observed that PTX-treated MSCs mediated
strong antitumorigenic effects because of their capac-
ity to take up the drug and later release it in EVs.84
In this study, PTX-loaded EVs induced a dose-
dependent inhibition of human pancreatic adenocar-
cinoma cell (CFPAC-1) proliferation and 50% inhibi-
tion of tumor growth in vivo. Furthermore, PTX-
loaded exosomes released from macrophages were
developed for PTX to treat multidrug resistant can-
cers.86 Exosomes were loaded with PTX using three
different methods: incubation at room temperature,
electroporation, and mild sonication. It was demon-
strated that a reformation of the exosomal mem-
branes upon mild sonication to preserve structure
and content of exosomal membranes resulted in high
loading efficiency and sustained drug release. Impor-
tantly, the incorporation of PTX into exosomes
(exoPTX) resulted in more than 50 times increases in
cytotoxicity in drug-resistant MDCKMDR1 (Pgp+)
cells. The increase in PTX cytotoxicity afforded by
exoPTX was greater in Pgp-overexpressing cells than
in their sensitive counterparts MDCKwt cells.
86 Strik-
ingly, the obtained results showed a nearly complete
co-localization of airway-delivered exosomes with
cancer cells in a model of murine Lewis lung carci-
noma (LLC) pulmonary metastases. Consequently,
exoPTX demonstrated superior inhibition of pulmo-
nary metastases growth in LLC mouse model. It was
hypothesized that three mechanisms are likely to
have significant impact on exoPTX anticancer activ-
ity, i.e., preferential accumulation of exoPTX in can-
cer cells, efficient delivery of the incorporated cargo
into target cancer cells, and bypassing Pgp-mediated
drug efflux in resistant cancer cells. In another inves-
tigation, exosomes derived from brain endothelial
cell line, bEND.3, were loaded with anticancer drugs
(Dox and PTX) and used for systemic delivery across
the BBB to treat gliomas in a xenotransplanted zebra-
fish model of brain cancer.83 Exosome-delivered
anticancer agents significantly decreased the fluores-
cent intensity of the cancer cells and tumor growth
marker. Finally, membrane vesicles loaded with
hydrophobic photosensitizers exhibited superior
phototherapeutic effects compared to the polymer-
based synthetic nanoparticles.85 Specifically, these
membrane vesicles were able to fuse with the plasma
membrane of cancer cells more effectively than
polymer-based synthetic nanoparticles. Drug-loaded
membrane vesicles accomplished co-delivery of
hydrophobic and hydrophilic compounds into the
cellular membrane and cytosol, respectively, largely
bypassing the endosome/lysosome pathway and
thereby enhancing the drug therapeutic efficacy in
both spheroids and in vivo tumors.85
Another therapeutic avenue involves the use of
exosomes to deliver exogenous small interfering
RNA (siRNA).37,87–94 Exosomes were suggested as
carriers for nucleic acids transfer, as they known to
naturally deliver mRNA, miRNA, various noncoding
RNA, mitochondrial DNA, and genomic DNA.95,96
Similar to the incorporation of genetic material into
living cells, electroporation of purified exosomes was
proposed for loading of exogenous RNA.91–94,97
Alvarez-Erviti et al. pioneered this method using elec-
troporation DC-derived exosomes in the presence of
siRNAs.94 The same method was used to load exo-
somes with miRNA to epidermal growth factor
receptor (EGFR) that is expressed breast cancer
cells.98 Next, exosomes are known to carry a nega-
tive surface charge, hence precluding electrostatic
siRNA complexation. Precomplexation of siRNA via
cationic liposomes followed by fusion with isolated
exosomes has been suggested for their loading with
siRNA by Wahlgren et al.87 The group reported the
efficient silencing of the target MAPK gene in mono-
cytes and lymphocytes using peripheral blood-borne
exosomes with incorporated exogenous siRNAs.87 In
another investigation, Shtam et al. introduced two
different exogenous siRNAs against RAD51 and
RAD52 into exosomes derived from HeLa cells.88
The exosome-delivered siRNA against RAD51 was
functional and caused massive cell death of recipient
cancer cells. The effect of EVs loaded with siRNA
targeted to miR-150, an oncomir, due to its promo-
tional effect on VEGF has also been reported.89,90 It
was demonstrated that the neutralization of miR-150
downregulated VEGF levels in mice and attenuated
angiogenesis. O’Brien et al.99 engineered EVs loaded
with miR-134, which is heavily downregulated in
breast cancer tissue as compared to healthy tissue. It
was demonstrated that miR-134-loaded EVs were
able to reduce STAT5B and Hsp90 levels in target
breast cancer cells and reduce cellular migration and
invasion. Furthermore, miR-134-loaded EVs
enhanced sensitivity of these cancer cells to the anti-
Hsp90 drugs, 17-AAG and PU-H71. Noteworthily,
this treatment did not significantly affect the cell pro-
liferation or cisplatin-induced apoptosis, unlike the
direct transfection of the target cells with miR-134.
Interestingly, exosomes released from HUVECs trea-
ted with chemotherapeutic agents, epirubicin and
PTX, were shown to induce antitumor responses dur-
ing breast cancer chemotherapy.100 Using miRNA
profiling, Bovy et al. identified specific miR-503,
which exhibited downregulated levels in exosomes
released from these endothelial cells. The exosome-
incorporated miR-503 impaired breast cancer cells
growth and decreased their invasive capacities.
In another study, adeno-associated viruses were
encapsulated in EVs (e.g., vexosomes) that displayed
viral capsid proteins. Notably, these vexosomes were
efficient for the delivery of genetic cargo into recipi-
ent cells.101 Aside of RNA, the incorporation of
exogenous DNA into EVs by electroporation was
also reported.102,103 Interestingly, the loading effi-
ciency and capacity of DNA in EVs was dependent
on DNA size—linear DNA molecules less than
1000 bp in length were more efficiently transferred
into EVs compared with larger linear DNAs and
plasmid DNAs.100 DNA-loaded EVs accomplished
transfer of DNA into recipient cells in vitro. Overall,
these reports indicate that exosomes may function as
exceptional gene delivery vectors that are safe, effi-
cient, organ/cell-specific, and nonimmunogenic.
Exosomes are also known to be nature’s way of
delivering different proteins.12 Consequently, loading
of exosomes released from autologous macrophages
with a therapeutic protein, catalase, ex vivo was
shown to produce potent anti-inflammatory and neu-
roprotective effects in murine models of Parkinson’s
disease (PD).104 The optimal loading procedure
included permeabilization of exosomal membranes
with saponin in the presence of catalase. Notably,
the loaded catalase was efficiently preserved against
proteases degradation by proteases. A considerable
amount of exosomes was detected in PD mouse brain
following intranasal administration. This resulted in
significant neuroprotective effects in in vitro and
in vivo models of PD. It was hypothesized that the
encapsulation of catalase into exosomes may pre-
serve catalase enzymatic activity, prolong the blood
circulation time, reduce immunogenicity, and
improve its interaction with epithelial cells, thus
improving drug transport and therapeutic
effects in PD.
The genetic modification of donor cells may
also be used for targeting exosomes to the disease
site. As an example, targeting of exosomes to the
brain was achieved by engineering the parental DCs
to express lysosomal-associated membrane protein 2 -
(Lamp2b), fused to the neuron-specific peptide
derived from rabies virus glycoprotein (RVG).94 Sys-
temically administered RVG-targeted exosomes deliv-
ered glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) siRNA specifically to neurons, microglia,
and oligodendrocytes in the brain, resulting in spe-
cific gene knockdown. The therapeutic potential of
exosome-mediated siRNA delivery was demonstrated
by the strong mRNA (60%) and protein (62%)
knockdown of BACE1, a therapeutic target in AD, in
wild-type mice.94 Similar approach was applied when
HEK 293T cell-derived exosomes expressing RVG-
Lamp2b fusion protein were utilized to deliver opioid
receptor μ (MOR) siRNA into the brain to treat mor-
phine addiction.105 These exosomes were able to
cross efficiently the BBB and transfer MOR siRNA
into the mouse brain. The delivered siRNA inhibited
morphine relapse via the downregulation of MOR
expression levels, indicating a potential for the use of
exosomes to treat drug addiction as well as other dis-
eases of the central nervous system. Next, exosomes
released from macrophages genetically modified to
express antioxidant, catalase, or glial cells-derived
neurotrophic factor were suggested for the treatment
of PD.106,107 Mechanistic studies revealed that exo-
somes secreted from pretransfected macrophages
contained the encoded therapeutic protein, as well as
its genetic material (DNA and mRNA) and NF-κb, a
transcription factor involved in the encoded gene
expression.106 Drug-loaded exosomes were able to
efficiently transfer their contents to contiguous neu-
rons resulting in de novo protein synthesis in target
cells.101 The transfected brain tissues showed month-
long expression of the encoded protein and pro-
longed attenuation of neuroinflammation (over
40 days) in mice with neuroinflammation.
This suggests that exosome-based formulations
have a potential to be a versatile strategy to treat var-
ious disorders. Nevertheless, significant efforts are
required and complex regulatory hurdles must be




Using exosomes as drug delivery vehicles takes
advantage of their natural carriage and extraordinary
ability to interact with target cells. It offers several
benefits over common drug administration regimens;
however, there are number of limitations and chal-
lenges that need to be addressed. One of the major
challenges in developing exosome-based formulations
is whether the sufficient number of exosomes can be
generated.108 Indeed, the exosome yield per cell will
impact the final production cost as well as clinical
applications. In this respect, the choice of parental
cells is critical. For example, MSCs are known to
produce large amounts of exosomes, suggesting that
these cells may be efficient for exosome production
in a clinically applicable scale.109 Next, extended cul-
turing of donor cells may considerably increase exo-
somal production. For example, culturing DCs for
extended time period28 or at low pH110 can increase
the exosomal production up to 10-fold. In another
study, the breakdown of parental cells (monocytes/
macrophages) loaded with anticancer agents, and iso-
lation of exosome-like nanoparticles allowed a 100-
fold higher production yield of the drug carriers.80
Finally, specifically designed bioreactors that resem-
ble bioreactors for tissue engineering111 can be uti-
lized for exosomes scale-up. Importantly, different
batches of exosomes can be pulled together, lyophi-
lized, and stored until their use in patients.104
As an alternative approach, MSCs may be har-
vested from bone marrow, propagated in culture to
obtain specific cell types, or even subtypes, and then
exosomes may be loaded with a therapeutic agent.
Although this approach would require a more inva-
sive procedure, a significant amount of as well as
storage of well-characterized exosomal carriers
would be possible.112 Furthermore, large-scale pro-
duction of therapeutically efficacious exosomes can
be achieved through the immortalization of donor
cells; for example, MSCs can be transfected by lenti-
virus carrying a MYC gene as reported in Ref 113.
MYC is a regulator gene that codes for a transcrip-
tion factor that plays a role in cell cycle progression.
The transfection allows for obtaining immortalized
cells but does not alter the fundamental characteris-
tics of these MSCs.113 In this case, a library of vari-
ous types of exosomal carriers for different drug
formulations could be developed in the future and
stored in stock for emergency situations. Finally, exo-
somes may be isolated from other sources (bovine
milk and crashed grapes), purified, loaded with a
drug, and used for oral or intranasal administration.
Next, efficient loading of exosomes without sig-
nificant changes in the structure and content of exo-
somal membranes is also a difficult task, as exosomes
consist of relatively tight and highly structured lipid
bilayers. It should be taken into consideration that
the disruption of the exosomes integrity during load-
ing procedures might alter their immune-privileged
status and, therefore, make them visible for the MPS.
Furthermore, exosomal carriers may lose their own
biological activity upon loading with a drug that
may diminish their ability to target disease tissues
and produce potent therapeutic effect. For example,
we demonstrated that biologically active exosomes
released by regenerative M2-subtype macrophages
can produce a potent synergistic neuroprotective
effect in mouse models of PD.104 Moreover, exo-
somes loaded with PTX were shown to target metas-
tases in a model of murine LLC pulmonary
metastases and efficiently eliminate cancer cells.86 It
was hypothesized that macrophage-released
exosomes are likely to have specific proteins on their
surface, which might allow for their preferential
accumulation in cancer cells. Therefore, preservation
of lipid and protein content of exosomal carriers may
be crucial for their therapeutic efficacy.
REGULATORY POINTS FOR
EXOSOME-BASED FORMULATIONS
Before bringing exosomes to clinic, it is important for
manufacturers to follow the appropriate FDA guide-
lines when producing exosome-based therapeutics.
Exosome-based therapies most likely fall under the
purview of The Office of Cellular, Tissue, and Gene
Therapies (OCTGT) within the FDA Center for Bio-
logics Evaluation and Research (CBER). The
OCTGT regulates cellular therapies, gene therapies,
therapeutic cancer vaccines, xenotransplants, combi-
nation products, and certain devices related to cell
and gene therapy. Exosomes themselves compose a
fairly heterogeneous population in terms of their bio-
chemical composition, the source (different cell lines
or patient samples) often dictates exosome pheno-
type114; this has critical implications for the use of
exosomes in the clinic. It should also be noted that
the absolute separation and definition of various EVs
(including exosomes) based on their size or biogene-
sis has yet to be established beyond doubt, and there
is currently no consensus on markers that distinguish
the origin of these vesicles once they have left the
cell.27
In order to manufacture exosomes, cell popula-
tions must be maintained for exosome harvest.
Because of the diversity in donor and tissue source,
certain information regarding the cell population
must be provided in order to ensure safety to the
patient. The type(s) of cells to be used should be clas-
sified as autologous, allogeneic, or xenogeneic in ori-
gin, and the tissue source or other relevant
information should also be provided. For donors,
any relevant characteristics of the donor(s) should be
specified, including age and sex. If a mixture of cells
or cell products from multiple donors is used, careful
attention must be payed to possible cell interactions
that may result in immune responses or other
changes that might alter the performance of the cells.
One must also include exclusion criteria for donors,
focusing on the presence or likelihood of infection by
HIV, hepatitis, etc. For autologous cells, one may
refer to 62 CFR 9721 for additional guidance on
adventitious agent testing and labeling. Cells should
be handled, propagated, and subjected to laboratory
procedures under conditions to minimize
contamination, and documentation should be pro-
vided. Structural and biological information about
the final exosome product should also be provided to
show that an appropriate and biologically active
form is present.
The manufacturing of exosomal formulations is
the key in fulfilling the industrial development of
exosomal drug formulations; purity, sterility,
potency, and identity of the manufacturing lots are
all crucial points to achieve in order to bring the drug
to clinic and must be tested. The overall scheme for
testing of exosome-based formulations is outlined in
Figure 2. The OCTGT should offer a flexible
approach to such testing due to the complex nature
of exosome-based products, similar to the flexibility
in testing allowed for cell-based therapies.
The reproducibility and consistency of the
product lots may be difficult to achieve as the starting
material may come from many different donors and
thus possesses inherent variability.115 For example,
Le Pecq116 evaluated the variability of the manufac-
turing process for over 100 separate exosomal lots
from blood cells of healthy volunteers. The analysis
of the data showed that the main source of variabil-
ity was related to the heterogeneity of the human
population, and not to the manufacturing process.
Therefore, if the exosomal drug formulation to be
administered to the patient is to be autologous, this
may reduce the difficulty in achieving reproducible
and consistent lots of exosomes.
The loading of drug into exosomes also repre-
sents a challenge in maintaining consistent and repro-
ducible lots, depending on the method of drug
loading and type of drug loaded into exosomes. If
loading nucleic acids, there may be lot-to-lot variabil-
ity in the purity and sequence of nucleic acids loaded,
the transfection efficiency may possess variability due
to impurities in the transfection reagent, and there
may also be variability in the bioassays used to char-
acterize drug loading. When loading small-molecule
drugs, lot-to-lot variability of the drug may be a con-
cern, as well as variability in the assays used to deter-
mine drug loading. Therefore, more rigorous
characterization of exosome-based formulations
using a combination of methods may be required.
Quality control of the lots is of paramount
importance in order to ensure safety and reproduci-
bility. Harvested exosomes should be assessed for
impurities and consistency, and any reagents used to
isolate or load exosomes with drug should undergo a
qualification program in order to ensure that they are
of the appropriate grade and quality for product con-
sistency. The manufacturing should be monitored by
in-process testing. Thus, the preparation of GMP-
grade exosomes from the ascites fluid of ovarian can-
cer patients and the methods used for the molecular
and immunological characterization of these exo-
somes preceding their use in clinical trials were
described by Navabi et al.117 Quality assessment of
the exosomes produced with this method has
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FIGURE 2 | The overall scheme of testing of exosome-based drug formulations in preclinical investigations.
demonstrated the consistent expression of MHC
Class I, CD81, and HSP70 molecules using Western
blotting. Because there is no way to sterilize the exo-
somal product postprocessing, aseptic technique
should be utilized throughout the manufacturing
process to maintain sterility; the use of closed manu-
facturing systems is encouraged. Testing for micro-
bial contamination is also imperative due to the
biological nature of the exosome product, which
requires extensive culture and manipulation.
The potency of exosomal drug formulations
must also be measured. According to FDA standards,
‘potency’ is defined as the products’ ‘specific ability
or capacity…to effect a given result.’118 The FDA
allows a ‘matrix approach’ to potency testing for
cell-based therapies, which exosomes may technically
fall under, looking at multiple characteristics and
cumulatively assessing them as a measure of potency.
Surrogate biomarkers (e.g., exosomal protein marker
expression) that correlate with biological activity can
be used to assess potency for exosome-based thera-
pies, which do not have any added drug. Those with
an added drug (e.g., PTX or curcumin) should also
test the concentration of drug in the final product as
well as activity of the final exosome product to assess
potency. There is currently no consensus on exosome
definitions and a lack of understanding regarding the
mechanisms of action of various exosome-based
therapies; thus, it may be difficult to assess the com-
position and bioactivity of the final exosome-based
therapeutic product. The OCTGT recommends test-
ing for characteristics that will help predicting the
safety and efficacy of the final product.
Identity testing is required in order to distin-
guish one product from another produced at the
same facility; however, this poses a challenge for cell
therapy and exosomal products because identity test-
ing may be unable to distinguish patient-specific lots
from one another. Tracking, labeling, and segrega-
tion systems must be implemented in order to avoid
mixing up patient-specific products. The FDA may
require a hold on the exosomal product in order to
complete identity and safety testing. This may also be
challenging for cell therapy products as the hold time
may affect their viability. However, exosome-based
products have been shown to be stable for extended
periods of time and are not as affected by the hold
time as cell therapy products. Significantly, exosomes
can be concentrated, lyophilized, and reconstituted in
water solutions, as this study demonstrated.104 This
will allow scalability, standardization, and consist-
ency of manufacturing different lots of exosomal
drug formulations, when a considerable amount and
long-turn storage of exosomes might be required. It
may still be wise to perform in-process testing during
critical junctures of the manufacturing process in
order to minimize the time it takes for the exosomal
product to be safely administered to the patient as
well as to collect valuable information about the
manufacturing process.
Toxicological in vivo evaluations are also
required to complete the safety examinations.
Although a patient may receive autologous exo-
somes, ex vivo manipulations may cause alterations
in the surface protein composition of the exosomes
or their morphology or result in aggregation and
other changes from the initial harvested naïve exo-
somes. These alterations may induce immune
response or cause toxicity; thus, a thorough evalua-
tion of their cytotoxicity, genotoxicity, and oxidative
damage should be assessed during preclinical studies.
Furthermore, exosomes themselves may induce an
unwanted immune response in the patient. To avoid
this effect, studies should be performed during clini-
cal trials to assess the immunogenicity of the
exosome-based therapy; antibody development
should be assessed both directly after administration
and at least 28 days afterward. Then, one should
determine, if the results are linked to any adverse
events, pharmacokinetics, or pharmacodynamics of
the exosome-based therapeutics.
Overall, there is currently a high degree of vari-
ability in terms of exosome sources, manufacturing
processes, and in vitro and in vivo product character-
ization, which poses a significant challenge to the
clinical translation of exosome-based therapies. An
established consensus or an FDA guidance regarding
these facets of exosome production would go far in
bringing exosome-based therapies to the clinic.
CONCLUSION
Exosome-based formulations are the next generation
drug delivery mechanism that combines nanoparticle
size with noncytotoxic effects, a high drug-carrying
capacity, and a low immunogenic profile. Significant
technological, functional, and safety features of this
therapeutics are still to be addressed. Thus, deficien-
cies in our knowledge of molecular mechanisms of
exosomes formation and a lack of methods to inter-
fere with the packaging of cargo hamper identifica-
tion of their physiological relevance in vivo.
However, they promise an unparalleled efficacy in
the treatment of many life-threatening conditions,
including those lacking effective pharmacotherapy.
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